Deregulation of the PI3K/Akt/mTOR pathway was associated with remarkable efficacy of mTOR inhibitors such as rapamycin or everolimus in bladder cancer cells in vitro and in xenograft models [17–20]. This evidence concerns the gene AKT1 and urinary bladder carcinoma.